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Abstract
Background and aims: The risk of hepatic steatosis may be reduced through changes to dietary intakes, but
evidence is sparse, especially for dietary patterns including the Mediterranean diet. We investigated the association
between adherence to the Mediterranean diet and prevalence of hepatic steatosis.
Methods: Cross-sectional analysis of data from two population-based adult cohorts: the Fenland Study (England, n= 9645,
2005–2015) and CoLaus Study (Switzerland, n= 3957, 2009–2013). Habitual diet was assessed using cohort-specific food
frequency questionnaires. Mediterranean diet scores (MDSs) were calculated in three ways based on adherence to the
Mediterranean dietary pyramid, dietary cut-points derived from a published review, and cohort-specific tertiles of dietary
consumption. Hepatic steatosis was assessed by abdominal ultrasound and fatty liver index (FLI) in Fenland and by FLI and
non-alcoholic fatty liver disease (NAFLD) score in CoLaus. FLI includes body mass index (BMI), waist circumference, gamma-
glutamyl transferase, and triglyceride; NAFLD includes diabetes, fasting insulin level, fasting aspartate-aminotransferase (AST),
and AST/alanine transaminase ratio. Associations were assessed using Poisson regression.
Results: In Fenland, the prevalence of hepatic steatosis was 23.9% and 27.1% based on ultrasound and FLI, respectively, and
in CoLaus, 25.3% and 25.7% based on FLI and NAFLD score, respectively. In Fenland, higher adherence to pyramid-based
MDS was associated with lower prevalence of hepatic steatosis assessed by ultrasound (prevalence ratio (95% confidence
interval), 0.86 (0.81, 0.90) per one standard deviation of MDS). This association was attenuated [0.95 (0.90, 1.00)] after
adjustment for body mass index (BMI). Associations of similar magnitude were found for hepatic steatosis assessed by FLI in
Fenland [0.82 (0.78, 0.86)] and in CoLaus [0.85 (0.80, 0.91)], and these were also attenuated after adjustment for BMI. Findings
were similar when the other two MDS definitions were used.
Conclusions: Greater adherence to the Mediterranean diet was associated with lower prevalence of hepatic steatosis, largely
explained by adiposity. These findings suggest that an intervention promoting a Mediterranean diet may reduce the risk of
hepatic steatosis.
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Introduction
Hepatic steatosis is a major cause of chronic liver disease
worldwide, with prevalence estimates ranging from 25 to
45% in the general population [1]. Hepatic steatosis, usu-
ally defined as fat accumulation > 5% in hepatocytes, is
the first recognisable stage for both alcoholic and
non-alcoholic fatty liver disease (NAFLD). Hepatic stea-
tosis, especially NAFLD, may lead to progressive liver fi-
brosis and cirrhosis and increased risk of type 2 diabetes
and cardiovascular diseases [2]. NAFLD is the primary
hepatic outcome of metabolic syndrome and further car-
diometabolic diseases, which include insulin resistance
as well as dyslipidaemia and obesity as key pathologic
mechanisms according to recent scientific advances [3,
4]. Previous dietary studies reported that, compared with
healthy controls, individuals with hepatic steatosis had a
higher consumption of carbohydrates, saturated fat,
meat, and soft drinks, along with a tendency towards a
lower intake of omega-3 polyunsaturated fatty acids
(PUFA) and fish [5–8]. However, there are few data con-
cerning associations between dietary factors and overall
dietary pattern with hepatic steatosis among healthy
adults.
Recently, the Mediterranean diet has been recom-
mended for the management of NAFLD by the
EASL-EASD-EASO Clinical Practice Guideline [3].
Meta-analyses and systematic reviews of published evi-
dence have supported a beneficial impact of adherence to
the Mediterranean diet on overall mortality and on risks
of metabolic syndrome, type 2 diabetes, and cardio-
vascular disease [9–11]. However, whether the
Mediterranean diet is associated with risk of hepatic
steatosis remains unclear. Higher adherence to the
Mediterranean diet has beneficial effects on the pro-
gression of hepatic steatosis, but this evidence was
derived from small-scale trials (n < 90 followed up for
< 6 months) in patients with existing hepatic steatosis
[12–17]. Among adults free from clinically manifest
hepatic steatosis, evidence from three studies is avail-
able, but still inconclusive. Two cross-sectional stud-
ies reported conflicting results: one among obese
Spanish adults with high cardiovascular risk (n = 794)
reported an inverse association [18], and the other
among apparently healthy Chinese adults (n = 332) re-
ported a null association [19]. The Framingham Heart
Study, only one longitudinal study thus far, has re-
cently reported a significant inverse association of
greater adherence to the Mediterranean diet with in-
cident hepatic steatosis (n = 1521 adults over 6 years
follow-up) [20].
Given the limited and inconsistent evidence, which is
mainly restricted to a single study or country, we aimed
to investigate the cross-sectional association of adher-
ence to the Mediterranean diet with hepatic steatosis
among middle-aged healthy adults in two independent
population-based cohorts: Fenland (East England, UK)
and CoLaus (Lausanne, Switzerland).
Methods
Study design and population
The Fenland Study is an ongoing population-based cohort
of adults from general practice lists in Cambridgeshire
(Cambridge, Ely, Wisbech, and surrounding villages) in
the UK [21]. Overall, 12,435 adults born between 1950
and 1975 (aged 30 to 65 years at recruitment) attended
baseline clinical assessments in 2005–2015. This cohort
was established to investigate environmental and genetic
risk factors for the development of type 2 diabetes and re-
lated metabolic disorders. Exclusion criteria were the pres-
ence of known diabetes, being pregnant, being unable to
walk unaided, or having psychosis or a terminal illness.
The Cambridge Local Research Ethics Committee ap-
proved the study (04/Q0108/19), and all participants pro-
vided written informed consent.
The CoLaus Study is an ongoing population-based co-
hort including a random sample of 6733 individuals aged
35 to 75 years in the city of Lausanne, Switzerland. Details
of the study have been described previously [22]. This co-
hort was established in 2003 to investigate the clinical,
biological, and genetic determinants of cardiovascular dis-
ease, and it included participants of European origin. For
the present analysis of CoLaus, we used data from the first
follow-up (study period 2009–2013; n = 5064) when diet-
ary assessment was initiated. The Institutional Ethics
Committee of the University of Lausanne approved the
study (reference 16/03), and all participants provided writ-
ten informed consent.
In this analysis of the two cohorts, we used standar-
dised exclusion criteria to remove participants with
diabetes [defined as glycated haemoglobin ≥ 48 mmol/
mol, fasting plasma glucose ≥ 7.0 mmol/L, 2-h glucose
≥ 11.1 mmol/L, or use of glucose-lowering drugs],
those who are pregnant, and those missing dietary data,
outcome data, or key covariates. We excluded those with
implausible energy intake based on sex-specific thresholds
(< 500 or > 3500 kcal/day in women; and < 800 or > 4000
kcal/day in men) [23]. Participants with missing marital
status data (n = 1506) in Fenland were retained for ana-
lyses and coded with a missing indicator variable.
Dietary assessment
In Fenland, a self-administered, 130-item, semi-quantitative
food frequency questionnaire (FFQ) was used to assess habit-
ual dietary intake over the previous year [24]. The validity of
the FFQ was previously assessed against 16-day weighed
dietary record, 24-h recall, and biomarkers [25–27]. In this
FFQ, the average consumption frequencies of each food item
ranging from ‘never or less than once per month’ to ‘six or
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more times per day’ (nine categories) were provided. Total
energy and macronutrient intake were estimated based on
the UK food composition database [28].
In CoLaus, a self-administered, 97-item, semi-quantitative
FFQ was used to assess dietary intake over the pre-
ceding 4 weeks [29], the validity of which had been
assessed in nearby Canton of Geneva against 24-h re-
calls [30, 31]. For each item, consumption frequencies
ranging from ‘less than once during the last 4 weeks’
to ‘two or more times per day’ (seven categories)
were provided, in addition to the serving size (smaller,
equal, or bigger) in comparison to a reference size.
Mediterranean diet scores
We calculated three Mediterranean diet scores (MDSs).
We evaluated the pyramid-based MDS (pyrMDS) [32]
based on the Mediterranean dietary pyramid [33] as our
primary exposure. The Mediterranean dietary pyramid
was proposed by the Mediterranean Diet Foundation to
be applied to both Mediterranean and non-Mediterranean
countries [33]. We previously confirmed the content val-
idity of pyrMDS in a non-Mediterranean setting, with its
higher scores being associated with lower incidence of car-
diovascular disease and cardiovascular and all-cause mor-
tality in a UK population [32]. The detailed scoring
method has been reported previously [32]. Briefly, a con-
tinuous score of 0 to 1 was assigned for each recom-
mended consumption level of the 15 components of the
pyramid (possible range 0–15): vegetables, legumes, and
fish as healthy food groups; red meat, processed meat, po-
tato, and sweets as unhealthy food groups; and fruits, ce-
reals, nuts, eggs, dairy, white meat, and alcoholic
beverages as items for which a moderate consumption
was recommended (Additional file 1: Table S1). The sec-
ond MDS was based on an algorithm proposed by Sofi
and Casini [34] based on a systematic review of the pub-
lished literature (literature-based MDS, LitMDS; possible
range 0–18). The LitMDS accounted for 9 dietary items:
vegetables, legumes, fruits and nuts, cereals, dairy, fish,
meat, alcohol, and olive oil. The third MDS was based on
each cohort’s sex-specific tertiles (tMDS; possible range
0–18) and accounted for the same 9 dietary items as
LitMDS (Additional file 1: Table S1). We also previously
tested these scores in a UK population [32]. The MDS cal-
culation was adjusted to an energy intake of 2000 kcal/day
(8.37MJ/day) based on the residual method [23, 32].
Ascertainment of hepatic steatosis
In Fenland, hepatic steatosis was ascertained by abdominal
ultrasound, which is considered the first-line diagnostic
procedure for hepatic steatosis [3]. A semi-quantitative
grading system was used to define normal hepatic echo-
texture or mild, moderate, and severe steatosis. The im-
ages were scored retrospectively according to standardised
criteria by two trained operators who were unaware of
other study measures. Hepatic steatosis scoring criteria
were (a) increased echotexture of the liver parenchyma
(bright liver in comparison with the kidney), (b) decreased
visualisation of the intra-hepatic vasculature, and (c) at-
tenuation of the ultrasound beam. Each criterion was
scored on a 4-point scale, and a cumulative liver fat score
based on the sum of the scores was created (possible
range 3–12) [35]. A score of ≤ 4 was classified as normal
liver, 5–7 as mild steatosis, 8–10 as moderate steatosis,
and ≥ 11 as severe steatosis. In our primary analysis, the
mild, moderate, and severe categories were grouped to-
gether. The diagnostic accuracy of ultrasound was previ-
ously assessed against proton magnetic resonance
spectroscopy, with sensitivity and specificity of 96% and
94%, respectively [36].
In both cohorts, we also evaluated fatty liver index (FLI)
as an outcome, using anthropometry measures and fasting
blood markers, calculated based on a logistic function in-
cluding body mass index (BMI), waist circumference
(WC), triglyceride (TG), and gamma-glutamyl transferase
(GGT) levels as follows:
FLI
¼ 1= 1þ e− 0:953 ln TGð Þþ0:139BMIþ0:718 ln GGTð Þþ0:053WC−15:745ð Þ
 
FLI × 100 ranged from 0 to 100, and the presence of
hepatic steatosis was defined by FLI ≥ 60, a value with
sensitivity and specificity of 61% and 86%, respectively
[37]. The diagnostic accuracy of FLI in comparison to
ultrasonography has been reported to have an area
under the receiver operating characteristic curve of
0.813 (95% CI 0.797, 0.830) [38].
In the CoLaus Study, abdominal ultrasound measure-
ments were not available and hepatic steatosis was
assessed by FLI (as above) and additionally by the ‘NAFLD
liver fat score’ [39]. The NAFLD liver fat score was based
on an algorithm including the presence of metabolic syn-
drome defined by the International Diabetes Federation
criteria [40], presence of type 2 diabetes, and fasting con-
centrations of insulin, aspartate-aminotransferase (AST),
and the AST/alanine transaminase (ALT) ratio:
NAFLD liver fat score ¼ −2:89þ 1:18metabolic syndrome
yes=noð Þ þ 0:45 type 2 diabetes
yes=noð Þ þ 0:15 fasting insulin
mU=Lð Þ þ 0:04 fasting AST
U=Lð Þ−0:94 AST=ALT
Compared to proton magnetic resonance imaging, the
presence of hepatic steatosis defined by a NAFLD liver
fat score greater than or equal to − 0.640 had a sensitiv-
ity of 86% and a specificity of 71% [39]. In Fenland, AST
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levels were not available to calculate NAFLD liver fat
score.
Assessment of covariates
In both studies, socio-demographic, lifestyle, and health
characteristics were collected by self-administered ques-
tionnaires. Socio-demographic data included age, sex,
marital status (single, married/cohabiting, and widowed/
separated/divorced), occupational social class (routine/
manual and administrative/professional in Fenland;
working and not working in CoLaus), and educational
level (compulsory, secondary, and university). Health
characteristics included the presence of metabolic syn-
drome and family history of diabetes. In the Fenland
Study, test site (Cambridge, Ely, and Wisbech) and
household income (< £20,000, £20,000–40,000, and >
£40,000) were also used as covariates. Smoking status
was classified as ‘never’, ‘former’, and ‘current’.
In Fenland, physical activity was assessed objectively
using combined heart rate and movement sensing for
over 6 days (Actiheart, CamNTech, Cambridge, UK)
with individual calibration for heart rate using a tread-
mill test [41]. To estimate intensity time series,
free-living data were pre-processed and modelled using
a branched equation framework then summarised over
time as daily physical activity energy expenditure (kcal/
day). In CoLaus, physical activity was assessed with a
validated self-administered quantitative physical activity
frequency questionnaire [41, 42].
In both cohorts, body weight and height were mea-
sured with participants barefoot and in light indoor
clothes; BMI was calculated as weight (kg) divided by
height squared (m2). Waist circumference was measured
by tape mid-way between the lowest rib and the iliac
crest. In Fenland, body fat mass was also measured with
dual-energy X-ray absorptiometry. Blood pressure was
measured three times using an automated oscillometric
sphygmomanometer in both cohorts, and the average of
the two last measurements was used to define systolic
and diastolic blood pressure.
Fasting venous blood samples were collected. In
Fenland, blood samples were placed on ice, centri-
fuged, and stored at − 70 °C until analysis. In CoLaus,
all assays were performed on the blood samples
within 2 h of blood collection. In both cohorts,
plasma TG, high-density lipoprotein cholesterol, and
glucose were measured using standard enzymatic
methods and ALT, AST (only in CoLaus), and GGT
were measured using reference method as standar-
dised by the International Federation of Clinical
Chemistry.
In both cohorts, alcohol consumption was assessed by
self-report number of alcoholic beverage units consumed
in the preceding week, categorised as ‘abstainers’ (0
unit/week), ‘moderate’ (1–21 units/week for men, 1–14
for women), and ‘heavy’ (> 21 units/week for men, > 14
for women) drinkers. We undertook two approaches re-
garding alcohol consumption: one as a covariate and the
second as a component of the MDS to evaluate adher-
ence to the Mediterranean diet from which alcohol con-
sumption was separated out as it is an established risk
factor for hepatic steatosis [1].
Statistical analysis
Statistical analyses were performed using Stata (version
14; StataCorp, College Station, TX). Descriptive statistics
were presented as mean ± standard deviation (SD) for
continuous variables and proportions for categorical var-
iables. Cohen’s kappa statistics were calculated to assess
the agreement between the FLI and ultrasound liver fat
score in Fenland and between the FLI and NAFLD liver
fat score in CoLaus.
Each of the three MDSs was modelled both categorically
(quintiles) and continuously (per SD). Multivariable-adjusted
Poisson regression was used to estimate the preva-
lence ratios (PR) and 95% confidence intervals (CI)
[43] and to examine the association between hepatic
steatosis (ultrasound liver fat score and FLI in Fen-
land; FLI and NAFLD liver fat score in CoLaus) as
dependent variables and the different MDSs (pyrMDS,
litMDS, and tMDS) as independent variables.
Analyses were adjusted for potential confounders in-
cluding age, sex, marital status, occupational status, edu-
cational level, smoking status, energy intake, and
physical activity energy expenditure (Fenland) or esti-
mated total energy expenditure (CoLaus). Further ad-
justments for BMI as potential confounder were also
conducted. In Fenland, the FFQ aimed at assessing ha-
bitual dietary intake across the previous year, whereas in
CoLaus, it was over the past 4 weeks. Hence, to adjust
for possible seasonal variation in CoLaus, the dates of
dietary intake assessment were included in regression
models.
A priori, we examined whether the association be-
tween adherence to the pyrMDS and hepatic steatosis
varied by alcohol consumption, testing for statistical
interaction by alcohol consumption and adherence to
the Mediterranean diet, and we also conducted analysis
stratified by alcohol consumption (abstainers, moderate,
and heavy drinkers). We also assessed the influence of
adjustment for both BMI and waist circumference; for
body fat mass (Fenland only); for alcohol consumption
(units/week); for clinical variables, including blood pres-
sure > 130/85 mmHg (yes/no), TG level > 1.7 mmol/L
(yes/no), high-density lipoprotein level < 1.29 mmol/L
for men and < 1.03 mmol/L for women (yes/no), and
glucose level ≥ 5.6 mmol/L (yes/no); and for family his-
tory of diabetes and metabolic syndrome (except for
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NAFLD liver fat score as metabolic syndrome is one of
its components).
We conducted sensitivity analyses excluding the alcohol
component from the pyrMDS to rule out the possible im-
pact of alcohol on the observed association; excluding par-
ticipants with BMI ≥ 30 kg/m2; excluding participants with
excessive alcohol consumption; including participants
with probable implausible energy intake; excluding partici-
pants with probable secondary causes of hepatic steatosis
such as hepatitis B or C, HIV, or hepatotoxic medications;
or including participants with diabetes (only for NAFLD
liver fat score in CoLaus). The British National Formulary
codes were used to identify hepatitis B and C or HIV in
the Fenland cohort and the Anatomical Therapeutic
Chemical classification of the World Health Organization
to identify hepatotoxic medications in the CoLaus Study.
Finally, we assessed the robustness of the results when
modelling ultrasound liver fat score (1) using 7 as the
cut-point to define hepatic steatosis (normal/mild vs.
moderate/severe), and (2) continuously, we also examined
the association of adherence to the Mediterranean diet
with ALT and GGT levels as crude markers of hepatic
steatosis [1, 44]. The latter were natural log transformed
prior to regression analysis.
Possible interactions between the different MDSs
with age, sex, and BMI in the main model were ex-
amined using the Wald test. We prespecified stratified
analyses if significant interaction was identified. Statis-
tical significance was considered for a two-sided test
with a p value < 0.05.
Results
Characteristics of included participants
Of the 12,435 participants in the Fenland Study, 2790
(22.4%) were excluded, leaving 9645 participants (54.4%
women; 48.9 ± 7.4 years) for analysis. Of the 5064 partici-
pants in CoLaus, 1107 (21.8%) were excluded, leaving 3957
participants (56.8% women; 57.0 ± 10.4 years) for analysis.
The reasons for exclusion are summarised in Additional file 1:
Figure S1, and the characteristics of included and excluded
participants are shown in Additional file 1: Table S2. The
mean pyrMDS score was 9.07 ± 1.43 and 8.45 ± 1.24 in
Fenland and CoLaus, respectively. In both cohorts, adher-
ence to the Mediterranean diet was higher among women
compared to men, positively correlated with socio-economic
status and negatively correlated with TG, liver enzyme levels,
BMI, waist circumference, prevalence of current smokers,
and prevalence of the metabolic syndrome (Table 1).
Adherence to the Mediterranean diet and prevalence of
hepatic steatosis
In Fenland, the prevalence of hepatic steatosis was
23.9% and 27.1% based on ultrasound and FLI, respect-
ively. Diagnoses using FLI and ultrasound liver fat score
were concordant (kappa = 0.79). In CoLaus, the preva-
lence of hepatic steatosis was 25.3% and 25.7% based on
FLI and NAFLD score, respectively, with high concord-
ance (kappa = 0.83) between the measures. Hepatic stea-
tosis was more prevalent among men; those with higher
BMI, waist circumference, and liver enzymes; and those
with metabolic syndrome (Additional file 1: Table S2).
In Fenland, the multivariable-adjusted analysis showed
an inverse association between pyrMDS quintiles and
hepatic steatosis based on ultrasound (ptrend < 0.001)
(Table 2), but the association was attenuated after fur-
ther adjustment for BMI (ptrend < 0.043). An inverse as-
sociation was also seen per one SD difference in
pyrMDS [PR of 0.86 (95% CI 0.81–0.90)] but was attenu-
ated after adjustment for BMI [0.95 (0.90, 1.00)].
In both cohorts, when FLI was the outcome, there was
an inverse association between pyrMDS quintiles and
hepatic steatosis (ptrend < 0.001) (Table 3), but the associ-
ation attenuated after adjustment for BMI (ptrend = 0.001
and 0.009 for Fenland and CoLaus, respectively). Signifi-
cant inverse association was seen per one SD difference
in the pyrMDS in both cohorts; the observed association
was attenuated but remained significant in Fenland after
adjustment for BMI (Table 3).
In CoLaus, when NAFLD liver fat score was the out-
come, there was a non-significant inverse association be-
tween pyrMDS quintiles and hepatic steatosis (ptrend =
0.022). Using pyrMDS as a continuous variable, there
was an inverse association per one SD difference [0.93
(0.87–0.99)], which attenuated after adjustment for BMI
(Table 3).
Associations using LitMDS or tMDS as exposure vari-
ables were largely consistent with those of pyrMDS
(Additional file 1: Table S3).
Other analyses
In both cohorts, analyses stratified by alcohol consump-
tion showed that the inverse association between pyrMDS
quintiles and hepatic steatosis was non-significant among
‘abstainers’ but significant among ‘moderate’ drinkers, ex-
cept for NAFLD liver fat score in CoLaus. Among ‘heavy’
drinkers, the results were inconsistent across the two co-
horts (Additional file 1: Table S4). Further adjustment for
BMI attenuated the inverse associations between pyrMDS
and hepatic steatosis within alcohol consumption strata.
Adjusting for both BMI and waist circumference at-
tenuated the associations (ptrend > 0.05), except for FLI
score in both studies (Additional file 1: Table S5). In
Fenland, the inverse association between pyrMDS and
hepatic steatosis as assessed by ultrasound remained sig-
nificant after adjusting for body fat mass (Add-
itional file 1: Table S5). Further adjustment for other
potential confounders or mediators including alcohol
consumption with and without adiposity measures,
Khalatbari-Soltani et al. BMC Medicine           (2019) 17:19 Page 5 of 14
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
pa
rt
ic
ip
an
ts
by
ad
he
re
nc
e
to
th
e
M
ed
ite
rr
an
ea
n
di
et
,F
en
la
nd
an
d
C
oL
au
s
st
ud
ie
s*
C
ha
ra
ct
er
is
tic
Fe
nl
an
d
St
ud
y
(n
=
96
45
)
C
oL
au
s
St
ud
y
(n
=
39
57
)
Q
1
(3
.3
0–
7.
84
)*
Q
2
(7
.8
5–
8.
73
)
Q
3
(8
.7
4–
9.
46
)
Q
4
(9
.4
7–
10
.2
8)
Q
5
(1
0.
29
–1
4.
03
)
Q
1
(1
.8
3–
7.
45
)
Q
2
(7
.4
6–
8.
18
)
Q
3
(8
.1
9–
8.
82
)
Q
4
(8
.8
3–
9.
47
)
Q
5
(9
.4
8–
12
.1
8)
A
ge
,y
ea
rs
48
.8
±
7.
5
48
.9
±
7.
3
48
.9
±
7.
5
48
.9
±
7.
6
49
.1
±
7.
5
58
.2
±
10
.7
58
±
10
.5
57
.4
±
10
.4
56
.3
±
10
.5
55
.1
±
9.
4
W
om
en
,%
35
.5
48
.1
57
.5
62
.0
69
.4
43
.1
54
.5
60
.1
60
.9
65
.5
M
ar
ita
ls
ta
tu
s,
%
†
Si
ng
le
7.
5
7.
5
5.
4
6.
9
8.
9
17
.3
12
.9
14
.4
17
.3
15
.0
M
ar
rie
d/
co
ha
bi
tin
g
66
.5
68
.7
70
.9
70
.2
69
.1
54
.3
57
.1
60
.1
59
.8
58
.2
Se
pa
ra
te
d
7.
3
7.
7
7.
9
7.
9
9.
5
28
.4
30
.0
25
.5
22
.9
26
.8
O
cc
up
at
io
n,
%
M
an
ag
er
ia
lo
r
pr
of
es
si
on
al
42
.5
54
.6
61
.3
66
.5
73
.8
–
–
–
–
–
Em
pl
oy
ed
–
–
–
–
–
53
.4
56
.9
55
.7
63
.1
67
.9
Ed
uc
at
io
n,
%
†
C
om
pu
ls
or
y
27
.8
22
.6
18
.6
14
.0
9.
2
18
.8
16
.6
15
.4
13
.4
11
.0
Se
co
nd
ar
y
55
.1
50
.7
46
.3
41
.1
36
.5
65
.0
64
.6
61
.2
58
.8
59
.8
U
ni
ve
rs
ity
17
.2
26
.7
35
.1
44
.9
54
.3
16
.2
18
.8
23
.4
27
.8
29
.2
A
nn
ua
li
nc
om
e,
%
†
<
£2
0,
00
0
16
.9
13
.6
11
.7
11
.4
9.
6
–
–
–
–
–
£2
0,
00
0–
40
,0
00
41
.7
35
.3
34
.2
30
.0
27
.5
–
–
–
–
–
>
£4
0,
00
0
38
.7
48
.3
52
.5
56
.6
61
.0
–
–
–
–
–
C
ur
re
nt
sm
ok
er
,%
20
.0
11
.4
10
.4
8.
8
6.
2
26
.4
22
.8
21
.0
18
.1
16
.4
A
lc
oh
ol
in
ta
ke
,u
ni
t/
w
ee
k‡
A
bs
ta
in
er
s
4.
1
4.
3
4.
5
3.
9
2.
6
21
.1
23
.3
24
.0
24
.5
24
.1
M
od
er
at
e
60
.5
61
.6
60
.7
60
.8
60
.7
62
.5
65
.9
69
.9
70
.8
72
.9
H
ea
vy
22
.7
25
.9
27
.5
27
.7
29
.5
16
.4
10
.9
6.
1
4.
7
2.
9
En
er
gy
in
ta
ke
,k
ca
l/d
ay
21
20
±
59
9
19
49
±
59
5
18
88
±
55
0
18
27
±
53
1
18
24
±
52
7
18
53
±
63
3
18
04
±
62
8
18
04
±
60
6
17
78
±
58
8
17
09
±
58
3
Pr
ot
ei
n,
%
en
er
gy
17
.6
±
3.
7
18
.2
±
3.
5
18
.3
±
3.
6
18
.2
±
3.
5
18
.0
±
3.
4
15
.6
±
3.
6
15
.8
±
3.
6
15
.5
±
3.
1
15
.5
±
3.
1
14
.9
±
2.
8
C
ar
bo
hy
dr
at
e,
%
en
er
gy
46
.6
±
7.
3
47
.6
±
6.
8
48
.2
±
6.
8
49
.0
±
6.
9
49
.3
±
6.
8
45
.1
±
9.
7
44
.9
±
9.
1
46
.7
±
8.
4
47
.0
±
8.
3
48
.3
±
8.
0
Fa
t,
%
en
er
gy
35
.3
±
5.
7
33
.9
±
5.
5
33
.1
±
5.
6
32
.6
±
5.
7
32
.6
±
5.
8
33
.3
±
6.
7
34
.7
±
6.
7
34
.6
±
6.
7
34
.6
±
6.
6
34
.5
±
6.
8
PA
EE
,k
ca
l/d
ay
10
48
±
90
3
87
8
±
75
0
77
7
±
66
8
74
0
±
58
2
69
6
±
51
5
TE
E,
kc
al
/d
ay
–
–
–
–
–
27
48
±
67
2
26
67
±
64
2
26
47
±
62
1
26
15
±
58
1
26
65
±
61
5
M
et
ab
ol
ic
sy
nd
ro
m
e,
%
§
42
.5
37
.8
31
.9
29
.7
22
.6
39
.5
37
.5
24
.0
28
.8
26
.0
BM
I,
kg
/m
2
27
.5
±
4.
6
27
.2
±
4.
7
26
.6
±
4.
5
26
.1
±
4.
3
25
.2
±
4.
2
26
.4
±
4.
4
26
.0
±
4.
4
25
.6
±
4.
1
25
.4
±
4.
2
25
.0
±
4.
1
W
ai
st
ci
rc
um
fe
re
nc
e,
cm
94
.5
±
13
92
.0
±
12
.9
89
.4
±
12
.5
87
.9
±
12
.1
85
±
11
.9
93
.4
±
12
.7
91
.4
±
12
.2
89
.7
±
11
.7
89
.1
±
12
.0
87
.8
±
11
.8
Tr
ig
ly
ce
rid
es
,m
m
ol
/L
1.
3
±
0.
9
1.
2
±
0.
8
1.
1
±
0.
7
1.
1
±
0.
6
1.
0
±
0.
6
1.
4
±
0.
9
1.
4
±
0.
8
1.
2
±
0.
7
1.
2
±
0.
9
1.
2
±
0.
7
Khalatbari-Soltani et al. BMC Medicine           (2019) 17:19 Page 6 of 14
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
pa
rt
ic
ip
an
ts
by
ad
he
re
nc
e
to
th
e
M
ed
ite
rr
an
ea
n
di
et
,F
en
la
nd
an
d
C
oL
au
s
st
ud
ie
s*
(C
on
tin
ue
d)
C
ha
ra
ct
er
is
tic
Fe
nl
an
d
St
ud
y
(n
=
96
45
)
C
oL
au
s
St
ud
y
(n
=
39
57
)
Q
1
(3
.3
0–
7.
84
)*
Q
2
(7
.8
5–
8.
73
)
Q
3
(8
.7
4–
9.
46
)
Q
4
(9
.4
7–
10
.2
8)
Q
5
(1
0.
29
–1
4.
03
)
Q
1
(1
.8
3–
7.
45
)
Q
2
(7
.4
6–
8.
18
)
Q
3
(8
.1
9–
8.
82
)
Q
4
(8
.8
3–
9.
47
)
Q
5
(9
.4
8–
12
.1
8)
G
G
T,
U
/L
39
.6
±
40
.8
36
.2
±
34
.4
32
.5
±
25
31
.9
±
25
.2
28
.5
±
22
.6
45
.3
±
72
.1
35
.3
±
33
.2
30
.8
±
28
30
.9
±
34
.7
28
.6
±
31
.1
A
LT
,U
/L
30
.8
±
16
.7
29
.1
±
15
.7
27
.7
±
14
.6
27
.2
±
15
.6
26
.1
±
16
.3
28
.9
±
22
.3
26
.9
±
15
.4
26
.1
±
13
.8
24
.8
±
12
.8
25
.3
±
14
.8
A
ST
,U
/L
–
–
–
–
–
30
.3
±
14
.8
28
.7
±
12
.3
28
.0
±
8.
7
27
.5
±
9.
3
27
.2
±
7.
6
PA
EE
ph
ys
ic
al
ac
tiv
ity
en
er
gy
ex
pe
nd
itu
re
,T
EE
to
ta
le
ne
rg
y
ex
pe
nd
itu
re
,B
M
Ib
od
y
m
as
s
in
de
x,
iq
r
in
te
rq
ua
rt
ile
ra
ng
e,
G
G
T
ga
m
m
a-
gl
ut
am
yl
tr
an
sf
er
as
e,
A
LT
al
an
in
e
am
in
ot
ra
ns
fe
ra
se
,A
ST
as
pa
rt
at
e
am
in
ot
ra
ns
fe
ra
se
*I
n
ea
ch
co
ho
rt
,p
ar
tic
ip
an
ts
w
er
e
ca
te
go
ris
ed
in
to
fiv
e
gr
ou
ps
by
qu
in
til
es
(Q
1
to
Q
5)
of
th
e
M
ed
ite
rr
an
ea
n
di
et
sc
or
e
re
pr
es
en
tin
g
th
e
le
ve
ls
of
di
et
ar
y
ad
he
re
nc
e
to
th
e
M
ed
ite
rr
an
ea
n
di
et
pa
tt
er
n
(d
ef
in
ed
by
th
e
M
ed
ite
rr
an
ea
n
di
et
py
ra
m
id
)
(p
os
si
bl
e
ra
ng
e
0
to
15
).
A
ra
ng
e
of
th
e
po
in
ts
in
ea
ch
ca
te
go
ry
is
pr
es
en
te
d.
D
at
a
ar
e
m
ea
n
±
SD
fo
r
co
nt
in
uo
us
va
ria
bl
es
or
pe
rc
en
t
fo
r
ca
te
go
ric
al
va
ria
bl
es
,u
nl
es
s
ot
he
rw
is
e
st
at
ed
†
D
ue
to
so
m
e
m
is
si
ng
da
ta
,n
um
be
rs
do
no
t
al
w
ay
s
ad
d
to
10
0%
.‘
Se
pa
ra
te
d
’i
nc
lu
de
d
di
vo
rc
ed
or
w
id
ow
ed
ad
ul
ts
‡
A
lc
oh
ol
co
ns
um
pt
io
n
ca
te
go
ris
ed
as
‘a
bs
ta
in
er
s’
(0
un
it/
w
ee
k)
,‘
m
od
er
at
e’
(1
–2
1
un
its
/w
ee
k
fo
r
m
en
,1
–1
4
fo
r
w
om
en
),
an
d
‘h
ea
vy
dr
in
ke
rs
’(
>
21
un
its
/w
ee
k
fo
r
m
en
,>
14
fo
r
w
om
en
)
§
M
et
ab
ol
ic
sy
nd
ro
m
e
de
fin
ed
ac
co
rd
in
g
to
th
e
In
te
rn
at
io
na
lD
ia
be
tic
Fe
de
ra
tio
n
Khalatbari-Soltani et al. BMC Medicine           (2019) 17:19 Page 7 of 14
Ta
b
le
2
A
ss
oc
ia
tio
n
be
tw
ee
n
ad
he
re
nc
e
to
th
e
M
ed
ite
rr
an
ea
n
di
et
an
d
pr
ev
al
en
ce
of
he
pa
tic
st
ea
to
si
s
de
fin
ed
by
ab
do
m
in
al
ul
tr
as
ou
nd
,F
en
la
nd
St
ud
y
Pr
ev
al
en
ce
ra
tio
(9
5%
C
I)
ac
ro
ss
qu
in
til
es
of
py
ra
m
id
-b
as
ed
M
ed
ite
rr
an
ea
n
di
et
sc
or
e*
p t
re
n
d
Pr
ev
al
en
ce
ra
tio
(9
5%
C
I)
pe
r
SD
di
ffe
re
nc
e*
Q
1
Q
2
Q
3
Q
4
Q
5
Ra
ng
e
of
sc
or
es
3.
30
–7
.8
4
7.
85
–8
.7
3
8.
74
–9
.4
6
9.
47
–1
0.
28
10
.2
9–
14
.0
3
N
to
ta
l
19
29
19
29
19
29
19
29
19
29
N
ca
se
s
(s
co
re
≥
5
of
3
to
12
)
60
2
54
7
45
0
39
1
31
3
M
ul
tiv
ar
ia
bl
e
+
SE
S
+
di
et
ar
y
fa
ct
or
†
1.
00
(re
f.)
0.
99
(0
.8
6,
1.
12
)
0.
82
(0
.7
1,
0.
95
)
0.
76
(0
.6
5,
0.
88
)
0.
67
(0
.5
6,
0.
78
)
<
0.
00
1
0.
86
(0
.8
1,
0.
90
)
M
ul
tiv
ar
ia
bl
e
+
BM
I‡
1.
00
(re
f.)
1.
02
(0
.8
9,
1.
16
)
0.
94
(0
.8
1,
1.
08
)
0.
90
(0
.7
7,
1.
04
)
0.
88
(0
.7
5,
1.
04
)
0.
04
3
0.
95
(0
.9
0,
1.
00
)
SE
S
so
ci
o-
ec
on
om
ic
st
at
us
,B
M
Ib
od
y
m
as
s
in
de
x
* In
ca
te
go
ric
al
an
al
ys
is
,t
he
po
pu
la
tio
n
w
as
di
vi
de
d
in
to
fiv
e
gr
ou
ps
by
qu
in
til
es
(Q
1–
Q
5)
of
th
e
M
ed
ite
rr
an
ea
n
di
et
sc
or
e,
st
an
da
rd
de
vi
at
io
n
is
1.
43
fo
r
th
e
M
ed
ite
rr
an
ea
n
di
et
sc
or
e
†
A
dj
us
te
d
fo
r
ag
e
(y
ea
rs
),
te
st
si
te
s
(C
am
br
id
ge
,E
ly
,a
nd
W
is
be
ch
),
se
x,
m
ar
ita
ls
ta
tu
s
(s
in
gl
e,
m
ar
rie
d,
an
d
di
vo
rc
ed
/w
id
ow
ed
),
oc
cu
pa
tio
na
ls
ta
tu
s
(r
ou
tin
e
an
d
pr
of
es
si
on
al
jo
bs
),
ed
uc
at
io
n
le
ve
l(
co
m
pu
ls
or
y,
se
co
nd
ar
y,
an
d
un
iv
er
si
ty
),
ho
us
eh
ol
d
in
co
m
e
(<
£2
0,
00
0,
£2
0,
00
0–
40
,0
00
,a
nd
>
£4
0,
00
0)
,s
m
ok
in
g
st
at
us
(n
ev
er
,f
or
m
er
,a
nd
cu
rr
en
t)
,e
ne
rg
y
in
ta
ke
(k
ca
l/d
ay
),
an
d
ph
ys
ic
al
ac
tiv
ity
en
er
gy
ex
pe
nd
itu
re
(k
ca
l/d
ay
)
‡
Fu
rt
he
r
ad
ju
st
ed
fo
r
BM
I.
Re
su
lts
of
fu
rt
he
r
ad
ju
st
m
en
t
fo
r
w
ai
st
ci
rc
um
fe
re
nc
e
w
er
e
br
oa
dl
y
in
lin
e
w
ith
of
th
e
fu
rt
he
r
ad
ju
st
m
en
t
fo
r
BM
I(
da
ta
no
t
sh
ow
n)
Khalatbari-Soltani et al. BMC Medicine           (2019) 17:19 Page 8 of 14
Ta
b
le
3
A
ss
oc
ia
tio
n
be
tw
ee
n
ad
he
re
nc
e
to
th
e
M
ed
ite
rr
an
ea
n
di
et
an
d
pr
ev
al
en
ce
of
he
pa
tic
st
ea
to
si
s,
Fe
nl
an
d
an
d
C
oL
au
s
st
ud
ie
s*
Pr
ev
al
en
ce
ra
tio
(9
5%
C
I)
ac
ro
ss
qu
in
til
es
of
py
ra
m
id
-b
as
ed
M
ed
ite
rr
an
ea
n
di
et
sc
or
e†
p t
re
n
d
Pr
ev
al
en
ce
ra
tio
(9
5%
C
I)
pe
r
SD
di
ffe
re
nc
e†
Q
1
Q
2
Q
3
Q
4
Q
5
Fe
nl
an
d
St
ud
y
Ra
ng
e
of
sc
or
es
3.
30
–7
.8
4
7.
85
–8
.7
3
8.
74
–9
.4
6
9.
47
–1
0.
28
10
.2
9–
14
.0
3
N
to
ta
l
19
29
19
29
19
29
19
29
19
29
FL
I,
m
ed
ia
n
(iq
r)‡
47
.6
(2
1.
1,
76
.4
)
39
.6
(1
6.
1,
69
.7
)
30
.6
(1
1.
9,
61
.3
)
25
.3
(1
0.
3,
55
.4
)
16
.9
(7
.5
,4
2.
2)
N
ca
se
s
(s
co
re
≥
60
)
77
3
63
2
49
6
42
4
28
5
M
ul
tiv
ar
ia
bl
e
+
SE
S
+
di
et
ar
y
fa
ct
or
§
1.
00
(re
f.)
0.
94
(0
.8
4,
1.
06
)
0.
81
(0
.7
1,
0.
92
)
0.
75
(0
.6
5,
0.
86
)
0.
52
(0
.4
4,
0.
62
)
<
0.
00
1
0.
82
(0
.7
8,
0.
86
)
M
ul
tiv
ar
ia
bl
e
+
BM
I‖
1.
00
(re
f.)
1.
00
(0
.8
8,
1.
12
)
0.
98
(0
.8
6,
1.
12
)
0.
94
(0
.8
2,
1.
08
)
0.
76
(0
.6
4,
0.
89
)
0.
00
1
0.
94
(0
.8
9,
0.
98
)
C
oL
au
s
St
ud
y
Ra
ng
e
of
sc
or
es
1.
83
–7
.4
5
7.
46
–8
.1
8
8.
19
–8
.8
2
8.
83
–9
.4
7
9.
48
–1
2.
18
N
to
ta
l
79
2
79
1
79
2
79
1
79
1
FL
I,
m
ed
ia
n
(iq
r)‡
43
.0
(1
9.
0,
72
.8
)
37
.2
(1
4.
9,
66
.5
)
30
.9
(1
3.
2,
56
.5
)
27
.4
(1
1.
7,
53
.7
)
22
.5
(9
.4
,4
9.
0)
N
ca
se
s
(s
co
re
≥
60
)
29
7
24
0
17
0
16
0
13
5
M
ul
tiv
ar
ia
bl
e
+
SE
S
+
di
et
ar
y
fa
ct
or
§
1.
00
(re
f.)
0.
93
(0
.7
7,
1.
12
)
0.
74
(0
.6
0,
0.
90
)
0.
73
(0
.5
9,
0.
90
)
0.
61
(0
.4
9,
0.
77
)
<
0.
00
1
0.
85
(0
.8
0,
0.
91
)
M
ul
tiv
ar
ia
bl
e
+
BM
I‖
1.
00
(re
f.)
1.
06
(0
.8
7,
1.
28
)
0.
90
(0
.7
4,
1.
11
)
0.
85
(0
.6
9,
1.
05
)
0.
79
(0
.6
3,
1.
00
)
0.
00
9
0.
94
(0
.8
8,
1.
00
6)
N
A
FL
D
liv
er
fa
t
sc
or
e,
m
ed
ia
n
(iq
r)*
*
−
1.
5
(−
2.
3,
−
0.
2)
−
1.
6
(−
2.
3,
−
0.
4)
−
1.
7
(−
2.
4,
−
0.
7)
−
1.
8
(−
2.
4,
−
0.
8)
−
2.
0
(−
2.
5,
−
0.
8)
N
ca
se
s
(s
co
re
≥
−
0.
64
0)
25
7
24
0
18
1
16
8
17
2
M
ul
tiv
ar
ia
bl
e
+
SE
S
+
di
et
ar
y
fa
ct
or
§
1.
00
(re
f.)
1.
03
(0
.8
6,
1.
25
)
0.
84
(0
.6
9,
1.
03
)
0.
82
(0
.6
7,
1.
01
)
0.
85
(0
.6
9,
1.
05
)
0.
02
2
0.
93
(0
.8
7,
0.
99
)
M
ul
tiv
ar
ia
bl
e
+
BM
I‖
1.
00
(re
f.)
1.
08
(0
.8
9,
1.
30
)
0.
92
(0
.7
5,
1.
12
)
0.
88
(0
.7
2,
1.
09
)
1.
02
(0
.8
2,
1.
26
)
0.
50
0.
98
(0
.9
1,
1.
04
)
FL
If
at
ty
liv
er
in
de
x,
iq
r
in
te
rq
ua
rt
ile
ra
ng
e,
SE
S
so
ci
o-
ec
on
om
ic
st
at
us
,B
M
Ib
od
y
m
as
s
in
de
x,
N
A
FL
D
no
n-
al
co
ho
lic
fa
tt
y
liv
er
di
se
as
e
*F
or
th
is
an
al
ys
is
,t
he
ou
tc
om
e
w
as
as
se
ss
ed
by
fa
tt
y
liv
er
in
de
x
an
d
N
A
FL
D
liv
er
fa
t
sc
or
e
**
C
al
cu
la
te
d
ba
se
d
on
an
al
go
rit
hm
in
cl
ud
in
g
pr
es
en
ce
of
th
e
m
et
ab
ol
ic
sy
nd
ro
m
e
an
d
ty
pe
2
di
ab
et
es
an
d
co
nc
en
tr
at
io
ns
of
fa
st
in
g
se
ru
m
in
su
lin
,f
as
tin
g
se
ru
m
as
pa
rt
at
e-
am
in
ot
ra
n
sf
er
as
e
(A
ST
),
an
d
A
ST
/a
la
ni
ne
-a
m
in
ot
ra
ns
fe
ra
se
ra
tio
†
In
ca
te
go
ric
al
an
al
ys
is
,t
he
po
pu
la
tio
n
w
as
di
vi
de
d
in
to
fiv
e
gr
ou
ps
by
qu
in
til
es
(Q
1-
Q
5)
of
th
e
M
ed
ite
rr
an
ea
n
di
et
sc
or
e,
st
an
da
rd
de
vi
at
io
n
is
1.
43
an
d
1.
24
fo
r
py
ra
m
id
-b
as
ed
M
ed
ite
rr
an
ea
n
di
et
sc
or
e
in
th
e
Fe
nl
an
d
an
d
C
oL
au
s
st
ud
ie
s,
re
sp
ec
tiv
el
y
‡
C
al
cu
la
te
d
ba
se
d
on
an
al
go
rit
hm
in
cl
ud
in
g
bo
dy
m
as
s
in
de
x,
w
ai
st
ci
rc
um
fe
re
nc
e,
tr
ig
ly
ce
rid
es
,a
nd
ga
m
m
a-
gl
ut
am
yl
tr
an
sf
er
as
e
§
A
dj
us
te
d
fo
r
ag
e
(y
ea
rs
),
se
x,
m
ar
ita
ls
ta
tu
s
(s
in
gl
e,
m
ar
rie
d/
co
ha
bi
tin
g,
an
d
di
vo
rc
ed
/w
id
o
w
ed
),
oc
cu
pa
tio
na
ls
ta
tu
s
(r
ou
tin
e
an
d
pr
of
es
si
on
al
jo
bs
in
th
e
Fe
nl
an
d
St
ud
y
an
d
w
or
ki
ng
an
d
no
t
w
or
ki
ng
in
th
e
C
oL
au
s
St
ud
y)
,e
du
ca
tio
n
le
ve
l(
co
m
pu
ls
or
y,
se
co
nd
ar
y,
an
d
un
iv
er
si
ty
),
sm
ok
in
g
st
at
us
(n
ev
er
,f
or
m
er
,a
nd
cu
rr
en
t)
,e
ne
rg
y
in
ta
ke
(k
ca
l/d
ay
),
ph
ys
ic
al
ac
tiv
ity
en
er
gy
ex
pe
nd
itu
re
(k
ca
l/d
ay
,i
n
th
e
Fe
nl
an
d
St
ud
y)
,t
ot
al
en
er
gy
ex
pe
nd
itu
re
(k
ca
l/d
ay
—
in
th
e
C
oL
au
s
St
ud
y)
,a
nd
da
te
of
di
et
ar
y
as
se
ss
m
en
t
(in
th
e
C
oL
au
s
St
ud
y)
‖ F
ur
th
er
ad
ju
st
ed
fo
r
BM
I.
Re
su
lts
of
fu
rt
he
r
ad
ju
st
m
en
t
fo
r
w
ai
st
ci
rc
um
fe
re
nc
e
w
er
e
br
oa
dl
y
in
lin
e
w
ith
of
th
e
fu
rt
he
r
ad
ju
st
m
en
t
fo
r
BM
I(
da
ta
no
t
sh
ow
n)
Khalatbari-Soltani et al. BMC Medicine           (2019) 17:19 Page 9 of 14
clinical variables, and presence of metabolic syndrome
partly attenuated the associations (Additional file 1:
Table S5). The results were not materially different
when excluding the alcohol component from the
pyrMDS; when excluding participants based on high
BMI ≥ 30 kg/m2, excessive alcohol consumption, or
secondary causes of hepatic steatosis; or when includ-
ing participants with implausible energy intakes or
with diabetes (Additional file 1: Table S5).
In Fenland, the use of a different dichotomisation of
the ultrasound liver fat score weakened the association
between pyrMDS quintiles and hepatic steatosis (Add-
itional file 1: Table S6). The association per SD of
pyrMDS was not altered, but CIs were widened (Add-
itional file 1: Table S6). Associations modelling ultra-
sound liver fat score as a continuous outcome variable
attenuated the inverse association, but it remained statis-
tically significant (ptrend < 0.001) (Additional file 1: Table
S6). Adherence to the Mediterranean diet was inversely
but not significantly associated with ALT and GGT
(Additional file 1: Table S7).
Finally, there were no significant interactions between
adherence to the Mediterranean diet and age or sex in
either cohort. A significant interaction between pyrMDS
and BMI was found in both cohorts (pinteraction < 0.05),
except when considering ultrasound liver fat score as an
outcome in Fenland (pinteraction = 0.33); hence, due to in-
consistent results, we conducted an analysis stratified by
BMI categories (underweight/normal, overweight, and
obese) (Additional file 1: Table S8).
In Fenland, the inverse association between pyrMDS
quintiles and hepatic steatosis was non-significant
(ptrend > 0.05) in the analyses stratified by BMI, except
among overweight participants when considering FLI as
an outcome (ptrend < 0.001). In CoLaus, considering FLI
as an outcome, a non-significant inverse association
between pyrMDS quintiles and hepatic steatosis was
found among underweight/normal (ptrend = 0.006) and
overweight participants (ptrend = 0.023). In contrast, con-
sidering NAFLD liver fat score as an outcome in
CoLaus, stratified analyses showed no significant associ-
ation between pyrMDS quintiles and hepatic steatosis
(ptrend > 0.05).
Discussion
In two independent population-based cohorts in the UK
and Switzerland, we found an inverse association be-
tween greater adherence to the Mediterranean diet and
the prevalence of hepatic steatosis. This association was
consistent across three different definitions of adherence
to the Mediterranean diet and with different non-inva-
sive criteria for assessing hepatic steatosis but was atten-
uated when we included measures of adiposity as a
covariate.
Comparison with other studies
Our findings add to the limited number of studies that
evaluated the associations between single food groups
or other dietary patterns and hepatic steatosis. A
cross-sectional study previously reported that an eating
pattern high in alcohol and meat intakes and with a low
tea consumption was associated with higher liver fat
content among 354 individuals from the PopGen co-
hort in Germany [45]. Another cross-sectional study
among Israeli adults reported a positive association be-
tween soft drink consumption and risk of NAFLD,
whereas higher intake of omega-3 polyunsaturated fatty
acids was negatively associated with the risk of NAFLD
[5]. Additionally, one Australian prospective study
among adolescents indicated that a Western dietary
pattern characterised by a high consumption of take-
away foods, confectionary, red or processed meat, re-
fined grain, chips, full-fat dairy, and soft drinks at age
14 was associated with the presence of NAFLD at age
17 years [46]. Our findings for the Mediterranean diet
are consistent with a recent secondary cross-sectional
analysis of the PREDIMED trial in Spain, although that
study focused on overweight and obese participants at
high cardiovascular risk, and assessed a dietary inflam-
matory index in conjunction with adherence to the
Mediterranean diet [18]. Moreover, our results are in
agreement with the only prospective study to date re-
ported a significant inverse association between adher-
ence to the Mediterranean diet and incident hepatic
steatosis among healthy individuals without hepatic
steatosis [20].
Nevertheless, our findings of an inverse association
between Mediterranean diet and hepatic steatosis were
not consistent with those from other studies. Possible
explanations may include differences in population and
methods. For instance, one cross-sectional study of
healthy Chinese adults in Hong Kong reported no sig-
nificant association between higher adherence to the
Mediterranean diet and NAFLD prevalence even in the
analyses without BMI adjustment [19]. This could be
because the authors defined MDS based on
population-specific medians of the study population,
which might be too crude [19, 32]. Additionally, a small
case-control study conducted in Athens compared 73
patients with NAFLD with 58 healthy controls and
found no association between greater MDS and lower
likelihood of having NAFLD [47].
In our study, the inverse association between adher-
ence to the Mediterranean diet and hepatic steatosis
was no longer significant after adjustment for adiposity
(BMI and waist circumference) suggesting that adipos-
ity may be a confounder or a mediator of the associ-
ation. While our study was not designed to distinguish
between these two phenomena, our findings were
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consistent with previous reports of non-significant as-
sociations between adherence to the Mediterranean diet
and NAFLD after adjustment for BMI or abdominal fat
[19, 47]. Our findings are also in agreement with a pre-
vious prospective study suggesting that the Western
dietary pattern acts predominantly on hepatic steatosis
incidence via the obesity pathway [46].
Previous studies have reported positive [48] or null [49]
associations between the Mediterranean diet and liver en-
zymes. The null associations reported previously are in
line with our results; the possible explanation could be the
normal levels of liver enzymes in the majority of individ-
uals with hepatic steatosis [50].
Possible mechanisms and implications
The potential mechanisms explaining the inverse as-
sociation of the individual components of the Medi-
terranean diet on hepatic steatosis have been
reviewed previously [51, 52]. Adherence to the Medi-
terranean diet is associated with high antioxidant cap-
acity and anti-inflammatory and anti-fibrotic effects
due to high fruit and vegetable consumption [53].
The Mediterranean diet is also associated with high
levels of monounsaturated fatty acids (MUFA), mostly
from olive oil intake. In animal models, high MUFA
from olive oil and/or PUFA improved lipid profile,
decreased cytokine expression in visceral adipocytes,
and decreased liver enzymes and hepatic TGs, thus
attenuating hepatic steatosis [54–56]. These results
have been corroborated in a meta-analysis of human
studies, which confirmed that omega-3 fatty acids
were negatively associated with hepatic steatosis [57].
Although epidemiological studies linking Mediterra-
nean diet to hepatic steatosis are scarce, there is
strong evidence regarding the inverse association be-
tween adherence to the Mediterranean diet and car-
diovascular disease, the metabolic syndrome, and its
components [9, 10, 58]. Few observational studies and
randomised clinical trials have evaluated the impact
of adherence to the Mediterranean diet on hepatic
steatosis progression [12, 48, 49, 59]. All these stud-
ies, despite their difference in study design, sample
population, outcome measure assessment methods,
and various Mediterranean diet-scoring methods, re-
ported the beneficial impact of greater adherence to
the Mediterranean diet on reduced progression of
hepatic steatosis. Thus, the Mediterranean diet may
represent an alternative therapy for hepatic steatosis,
given the well-recognised problems of achieving sus-
tainable weight loss, which is currently the primary
treatment for hepatic steatosis through lifestyle ther-
apy involving diet and exercise. Therefore, the clinical
importance of the Mediterranean diet for the preven-
tion of hepatic steatosis deserves further discussion.
Strengths and limitations
Our study in two population-based cohorts in two in-
dependent settings of the UK and Switzerland, to-
gether with the large sample size of nearly 14,000
participants, allowed us to conduct stratified analysis
with adequate statistical power. The application of
three different scoring algorithms for the Mediterra-
nean diet enhanced the utility of representing adher-
ence to the diet in different epidemiological settings.
Finally, the consistency of the findings in two inde-
pendent cohorts suggests that the results may be rea-
sonably generalisable to other populations.
Our study also has some limitations. First, its
cross-sectional design precludes any causal interpret-
ation of the association between adherence to the
Mediterranean diet and hepatic steatosis. The study de-
sign was also limited by its inability to distinguish
whether adiposity mediated or confounded the ob-
served association. Second, hepatic steatosis was based
on different indicators and not on liver biopsy, which is
considered to be the gold standard technique. However,
liver biopsy is an invasive method, which cannot be im-
plemented in large-scale epidemiological studies with
predominantly healthy participants. In the Fenland
Study, hepatic steatosis was based on ultrasound, a
valid method for detecting hepatic steatosis [36], sup-
plemented with an algorithm-based FLI, while in the
CoLaus Study, two hepatic steatosis indices were used.
These validated markers of hepatic steatosis are based
on non-invasive and easily ascertained measurements
which make them suitable for large epidemiological
studies [38, 39, 60, 61], and the results were consistent
irrespective of the marker used. Third, excluding partic-
ipants with diabetes might have led to an underestima-
tion of hepatic steatosis prevalence as assessed by
NAFLD liver fat score and its association with the
Mediterranean diet. However, findings were similar
upon including participants with diabetes in the sensi-
tivity analysis. Fourth, the methods for measuring vari-
ables (e.g. physical activity) differed between cohorts;
however, the consistency of our findings suggests that
the impact of the differing methods on results was min-
imal. Fifth, self-reported dietary intake and covariates
are prone to measurement errors but the instruments
used were validated against reference methods, and we
found consistency of our estimates across the levels of
adjustments.
Conclusion
Greater adherence to the Mediterranean diet was
associated with lower likelihood of hepatic steatosis,
and this association was largely related to markers of
adiposity. These cross-sectional findings were strength-
ened by their consistency in two independent settings
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in the UK and Switzerland and are hypothesis generating
for the role of the Mediterranean diet in hepatic steatosis in
non-Mediterranean settings. The cross-sectional find-
ings from our population-based cohorts warrant further
interventional or observational studies to test whether
the improvement of adherence to the Mediterranean diet
is efficacious and effective in diverse settings for the pri-
mary prevention of hepatic steatosis.
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